PTC Therapeutics Grants Stock Options and RSUs to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Stock Option Grant: On December 16, 2025, PTC Therapeutics approved the grant of 3,825 stock options and 4,385 restricted stock units to five new employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Structure: All stock options have an exercise price of $75.42 per share, aligning with Nasdaq's inducement grant exception, reflecting the company's commitment to incentivizing new hires.
- Long-term Vesting: The stock options vest over four years, with 25% vesting in the first year and 6.25% every three months thereafter, ensuring continued employee contribution during their tenure.
- Strategic Talent Acquisition: This grant of stock options and RSUs not only enhances the company's ability to attract and retain key talent but also supports its innovative development in the rare disease sector.
PTCT
$78.57+Infinity%1D
Analyst Views on PTCT
Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 74.590
Low
50.00
Averages
76.18
High
118.00
Current: 74.590
Low
50.00
Averages
76.18
High
118.00
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
